Nasdaq

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase ...

Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Monthly Prescribing Reference

Keytruda Approved for First-Line Treatment of Advanced HER2-Negative Gastric Cancer

Keytruda approved for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma. The Food and Drug Administration (FDA) has approved Keytruda ...
Nasdaq

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction ...

If approved, a KEYTRUDA combination would become an option in the EU for the treatment of both HER2-negative and HER2-positive advanced gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (CPS ≥1 ...
Cure Today

First-Line Lenvima Plus Keytruda Misses Mark in Endometrial Cancer

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
WebMD

How Keytruda and Keytruda Qlex Work for Lung Cancer

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...